Overview

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

Status:
RECRUITING
Trial end date:
2027-08-23
Target enrollment:
Participant gender:
Summary
MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.
Phase:
PHASE1
Details
Lead Sponsor:
Merck Sharp & Dohme LLC